Last reviewed · How we verify
VNZ/TEZ/D-IVA
VNZ/TEZ/D-IVA is a triple combination therapy consisting of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, a corrector, and a potentiator.
VNZ/TEZ/D-IVA is a triple combination therapy consisting of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, a corrector, and a potentiator. Used for Cystic fibrosis.
At a glance
| Generic name | VNZ/TEZ/D-IVA |
|---|---|
| Also known as | Vanzacaftor/Tezacaftor/Deutivacaftor, VX-121/VX-661/VX-561, VX-121/VX-661/CTP-656, Vanzacaftor/tezacaftor/deutivacaftor, vanzacaftor/tezacaftor/deutivacaftor |
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Drug class | CFTR modulator |
| Target | CFTR |
| Modality | Small molecule |
| Therapeutic area | Cystic Fibrosis |
| Phase | Phase 3 |
Mechanism of action
The CFTR modulator, tezacaftor, corrects the defective protein, while the corrector, ivacaftor, helps the protein reach the cell surface. The potentiator, elexacaftor, increases the activity of the corrected protein.
Approved indications
- Cystic fibrosis
Common side effects
- Upper respiratory tract infection
- Nausea
- Headache
Key clinical trials
- Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants (PHASE1)
- Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older (PHASE3)
- A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA) (PHASE1)
- A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VNZ/TEZ/D-IVA CI brief — competitive landscape report
- VNZ/TEZ/D-IVA updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI